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Migraine is a common chronic neuronal disorder with episodic
attacks affecting the one tenth of the general population with
enormous social impact. The management of the disorder
includes several approaches, both behavioral and pharmaceutical
interventions, preventive or symptomatic ones. Exceptionally,
invasive treatments may be required as well. A plentiful pallet of
pharmacological agents covers symptomatic treatment, further
divided into specific and nonspecific anti-migraine agents. Apart
from triptans, ergot alkaloids are also included in the specific
anti-migraine drugs. Triptans, share a common pharmacological
profile targeting to 5-HT1B/1D/1F receptors with different phar-
macokinetic and pharmacodynamic properties resulting to slight
diverse efficacy and safety that may be important for the treat-
ment goals. Triptans are recommended as initial treatment for
moderate to severe migraine attacks, or when other agents failed
to reach the expected therapeutic benefit in less-disabled
patients. For migraine prophylaxis valproate, topiramate and
flunarizine are recommended. In the case of chronic migraine, a
disabling subform of migraine, with or without medication
overuse, onabotulinumtoxinA and topiramate are suggested. A
variety of behavioral treatments are available for those patients
they experience increased stress in particular. Although numer-
ous, the above treatments may not be enough to manage
migraine appropriately even in the right hands, rising needs for
future treatments with improved efficacy and safety profile.
CGRP antagonists and specific 5-HT1F agonists are potential
future symptomatic agents for migraine.
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